维普中文期刊产品整合服务
1250篇 您的检索式:作者名="CHAPMAN C"
    题名 作者 年代 出处 被引量
1Sleep disorders and chronic kidney disease显示文摘Sleep disorders have a profound and well-documented impact on overall health and quality of life in the general population. In patients with chronic disease, sleep disorders are more prevalent, with an additional morbidity and mortality burden. The complex and dynamic relationship between sleep disorders and chronic kidney disease(CKD) remain relatively little investigated. This article presents an overview of sleep disorders in patients with CKD, with emphasis on relevant pathophysiologic underpinnings and clinical presentations. Evidence-based interventions will be discussed, in the context of individual sleep disorders, namely sleep apnea, insomnia, restless leg syndrome and excessive daytime sleepiness. Limitations of the current knowledge as well as future research directions will be highlighted, with a final discussion of different conceptual frameworks of the relationship between sleep disorders and CKD.Stephanie C Maung Ammar El Sara Cherylle Chapman Danielle Cohen Daniel Cukor 2016World Journal of Nephrology2016,5,3:13
2评估清晨或夜晚服用降压药对24h动态血压的影响:清晨或夜间服用降压药的希腊英国联合研究显示文摘观察数据显示,临床血压水平与随后的主要不良心血管事件之间存在强烈的线性关系。然而,动态血压监测显示,夜间血压水平比24h或白天血压水平更能预测主要的不良心血管事件。此外,夜间与白天的血压比值和杓型状态也是心血管结局的重要独立预测因素。这些发现可能对抗高血压药物的最佳给药时间有影响,一些研究表明,夜晚服用降压药可能较白天服药减少心血管事件。Poulter NR Savopoulos C Anjum A Apostolopoulou M Chapman N Cross M Falaschetti E Fotiadis S James RM Kanellos I Szigeti M Thom S Sever P Thompson D Hatzitolios AI 赵狄 练桂丽 2018中华高血压杂志2018,26,10:7
3Current surgical treatment strategies for hepatocellular carcinoma in North America显示文摘Hepatocellular carcinoma(HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease.Many patients do not initially manifest any symptoms of HCC and present late when cure with surgical resection or transplantation is no longer possible.For this reason,patients at high risk for developing HCC are subjected to frequent screening processes.The surgical management of HCC is complex and requires an inter-disciplinary approach.Hepatic resection is the treatment of choice for HCC in patients without cirrhosis and is indicated in some patients with early cirrhosis(Child-Pugh A).Liver transplantation has emerged in the past decade as the standard of care for patients with cirrhosis and HCC meeting Milan criteria and in select patients with HCC beyond Milan criteria.Loco-regional therapy with transarterial chemoembolization,transarterial embolization,radiofrequency ablation and other similar local treatments can be used as neo-adjuvant therapy to downstage HCC to within Milan criteria or as a bridge to transplantation in patients on transplant wait list.Adeel S Khan Kathryn J Fowler William C Chapman 2014World Journal of Gastroenterology2014,20,41:3
4Vemurafenib改善伴BRAF V600E突变的黑色素瘤患者的生存率显示文摘背景 BRAF激酶抑制剂vemurafenib(PLX4032)的1期和2期临床试验已证实其对伴BRAFV600E突变的转移性黑色素瘤患者的反应率超过50%。方法我们在675例既往未经治疗、伴BRAFV600E突变的转移性黑色素瘤患者中,实施了一项Ⅲ期随机化临床试验以比较vemurafenib和Dacarbazine(氮烯唑胺)。患者通过随机分配,分别接受vemurafenib(每次口服960mg,每天两次)或氮烯唑胺(每3周静脉注射1000mg·m-2体表面积)。本研究主要终点是比较总体生存率及无进展期生存率。次要终点包括反应率、反应持续时间以及安全性。计划在死亡98例患者时进行中期分析、死亡196例时进行最终分析。结果在治疗6个月后,vemurafenib组总体生存率为84%(95%置信区间[CI],78-89),而氮烯唑胺组为64%(95%CI,56-73)。在对总体生存率的中期分析及无进展期生存率的最终分析中,与氮烯唑胺相比,vemurafenib能相对减低63%的死亡风险,以及减低74%的死亡或者疾病进展风险(两种比较P<0.001)。通过数据及安全监督委员会进行独立中期分析审查后,建议氮烯唑胺组患者也转而服用vemurafenib。对Vemurafenib反应率是48%而氮烯唑胺只有5%。伴Vemurafenib常见不良反应为关节痛、皮疹、疲劳、脱发、角化棘皮瘤或鳞状细胞癌、光过敏、恶心和腹泻;38%的患者因为毒副作用要求调整剂量。结论 Vemurafenib能改善既往未经治疗、伴有BRAFV600E突变的黑色素瘤患者的总体及无进展期生存率。(本研究由瑞士罗氏制药有限公司资助;BRIM-3临床试验编号:NCT01006980)涂超 Chapman PB Hauschild A Robert C 2011肿瘤药学2011,1,5:2
5Sequence-and region-specificity of oxaliplatin in naked and cellular DNA显示文摘Woynarowski JM Chapman WG Napier C 1998Mol Pharmacol1998,54,5:2
6Reflected Blast Wave Resultants Behind Cantilever Walls:A New Prediction Technique 显示文摘CHAPMAN T C ROSE T A SMITHS P D 1995International Journal of Impact Engineering1995,16,3:1
7Design engineering-a need to rethink the solution using knowledge based engineering显示文摘CHAPMAN C B PINFOLD M 1999Knowledge-Based Systems1999,12,:1
8Phase Ⅰ study of paclitaxel and estramustine:preliminary activity in hormone-refractory prostate cancer显示文摘Hudes G R Obasaju C Chapman A 1995Semin Oncol1995,22,:1
9Correlative memory deficits,αβelevation,and amyloid plaques in transgenic mice显示文摘Hsiao K Chapman P Eckman C 1996Science1996,274,5284:1
10Infection of the Norway lobster Nephrops norvegicus by a Hematodinium-like species of dinoflagellate on the west coast of Scotland 显示文摘Field R H Chapman C J Taylor AC 1992Dis Aquat Org1992,13,:1
11DNA binding- dependent and - independent functions of the Hand2 transcription factor during mouse embryogenesis显示文摘LIU N BARBOSA A C CHAPMAN S L 2009Development2009,136,6:1
12Can we use influen-cing factors to predict aspiration pneumonia in the UnitedKingdom显示文摘Hibberd J Fraser J Chapman C 2013Multidiscip Respir Med2013,8,1:1
13Immunobiomarkers in small cell lung cancer: potential early cancer signals 显示文摘Chapman C J Thorpe AJ Murray A 2011Clin Cancer Res2011,17,6:1
14Improved survival with vemurafenib in melanoma with BRAF V600E mutation 显示文摘Chapman PB Hauschild A Robert C 2011N Engl J Med2011,364,:1
15Pseudomigraine with lymphocytic pleocytosis:a calcium channelopathy? Clinical description of 10 cases and genetic analysis of the familial hemiplegic migraine gene CACNA1A显示文摘Chapman KM Szczygielski BI Toth C 0,,:1
16Treatment of esopha- geal cancer based on histology: a surveillance epidemiology and end results analysis 显示文摘Chang D T Chapman C Shen J 2009American Journal of Clinical Oncolo- gy2009,32,4:1
17Does early fracture fixation of thoracolumbar spine fractures de- crease morbidity or mortality? 显示文摘Bellabarba C Fisher C Chapman JR 2010Spine (Phila Pa 1976)2010,35,9:1
18Generalized Born Scat- tering of Elastic Waves in 3-D Media显示文摘Coates R T Chapman C H 1991Geophysical Journal International1991,107,:1
19Continuum structural topology design with genetic algorithms 显示文摘Jakiela M J Chapman C Duda J Adewuya A 2000Computer Methods in Applied Mechanics and Engineering2000,186,:1
20Consistent antibody response against ganglio-side GD2 induced in patients with melanoma by a GD2 lactonekeyhole limpet hemoeyanin conjugate vaccine plus immunological adjuvant QS-21 显示文摘Ragupathi G Livingston PO Hood C Gathuru J Krown SE Chapman PB 2003Clin Cancer Res2003,9,14:1
返回顶部 每页显示:
共63页 首页 上一页 第1页 下一页 末页 /63 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费